This opinion piece by Dr Scott Gottlieb, a Pfizer board member, may be biased towards the pharmaceutical industry 🤔

“FDA’s permissive stance on the compounding of GLP-1 drugs used for weight loss. Initially, the agency cited shortages of semaglutide and tirzepatide — the active ingredients in the popular drugs Wegovy and Zepbound — and allowed pharmacies to compound these drugs under a provision for addressing drug shortages.”